Full metadata record

DC Field Value Language
dc.contributor.authorYang, YJ-
dc.contributor.authorLee, SH-
dc.contributor.authorHong, SJ-
dc.contributor.authorChung, BC-
dc.date.accessioned2024-01-21T15:11:23Z-
dc.date.available2024-01-21T15:11:23Z-
dc.date.created2021-09-05-
dc.date.issued1999-08-
dc.identifier.issn0009-9120-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/142035-
dc.description.abstractObjective: The role of dietary fatty acids (FAs) in benign and malignant prostatic diseases was investigated by comparing the composition Value of serum fatty acids in the normal controls, and patients with prostate cancer (PC) and benign prostatic hyperplasia (BPH). Also, to estimate a possible association between PG risk and PUFAs, omega-3, omega-6 and omega-3/omega-6 FA composition ratios were compared among these groups. Methods: Serum samples were obtained from 24 BPH and 19 PC patients, and from 21 age-matched normal male subjects. The serum concentration of 21 fatty acids was determined using gas chromatography/mass spectrometry. Result: The proportional Values of saturated fatty acids (SFAs) groups demonstrated no specific difference between the control subjects and the patients. In the polyunsaturated far, acids (PUFAs), we found that the w-3 PUFAs level was significantly decreased in patient with BPH and PC and that the w-6 PUFAs level was increased in PC only. The ratio of omega-3/omega-6 PUFAs decreased in the following order of normal, BPH, and PC. Conclusion: It was proposed that the changed composition level of PUFAs including omega-3 and w-6 PUFAs have certain relationship with both prostatic diseases. Therefore, the ratio of omega-3/omega-6 PUFAs also may have an important association with the benign and malignant status of prostatic disease. Copyright (C) 1999 The Canadian Society of Clinical Chemists.-
dc.languageEnglish-
dc.publisherPERGAMON-ELSEVIER SCIENCE LTD-
dc.subjectN-3-
dc.subjectPHOSPHOLIPIDS-
dc.subjectOMEGA-3-
dc.subjectGROWTH-
dc.subjectRISK-
dc.titleComparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia-
dc.typeArticle-
dc.identifier.doi10.1016/S0009-9120(99)00036-3-
dc.description.journalClass1-
dc.identifier.bibliographicCitationCLINICAL BIOCHEMISTRY, v.32, no.6, pp.405 - 409-
dc.citation.titleCLINICAL BIOCHEMISTRY-
dc.citation.volume32-
dc.citation.number6-
dc.citation.startPage405-
dc.citation.endPage409-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000083512400002-
dc.identifier.scopusid2-s2.0-0005224832-
dc.relation.journalWebOfScienceCategoryMedical Laboratory Technology-
dc.relation.journalResearchAreaMedical Laboratory Technology-
dc.type.docTypeArticle-
dc.subject.keywordPlusN-3-
dc.subject.keywordPlusPHOSPHOLIPIDS-
dc.subject.keywordPlusOMEGA-3-
dc.subject.keywordPlusGROWTH-
dc.subject.keywordPlusRISK-
dc.subject.keywordAuthorprostate cancer-
dc.subject.keywordAuthorbenign prostatic hyperplasia-
dc.subject.keywordAuthorfatty acids-
dc.subject.keywordAuthorgas chromatography/mass spectrometry-
Appears in Collections:
KIST Article > Others
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE